News ArticleBiocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Dr. Mandar Ghatnekar to step down as CTO on December 31, 2026; Mukesh Rathi appointed effective January 1, 2027
Biocon Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, reporting a standalone profit of Rs. 917 million for the quarter. The company also disclosed the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as new CTO starting January 1, 2027.
Biocon Limited
General / Other
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
The company reported total standalone revenue from operations of Rs. 6,305 million for the quarter ended September 30, 2026, and Rs. 12,550 million for the half-year. Total standalone profit before tax was Rs. 1,198 million for the quarter.
Profit after tax for the quarter was Rs. 917 million, with earnings per share (basic and diluted) at Rs. 0.56 for the quarter and Rs. 0.88 for the half year.
The board meeting commenced at 11:20 A.M. and concluded at 1:10 P.M. on November 4, 2026.
Changes in senior management include the resignation of Dr. Mandar Shrikant Ghatnekar as Chief Technology Officer, effective December 31, 2026. Mr. Mukesh Rathi will assume the position from January 1, 2027.
Mr. Mukesh Rathi brings over 27 years of experience in digital transformation, AI-led innovation, and technology management, having served as Group Chief Digital Officer at Hinduja Group and in senior roles at Dr. Reddy’s Laboratories.
Highlights
- Standalone revenue from operations for Q2 2026: Rs. 6,305 million
- Standalone profit after tax for Q2 2026: Rs. 917 million
- Earnings per share (basic and diluted) for Q2 2026: Rs. 0.56
- CTO Dr. Mandar Ghatnekar to resign effective December 31, 2026
- Mukesh Rathi appointed as new CTO effective January 1, 2027
- Board meeting held on November 4, 2026, from 11:20 A.M. to 1:10 P.M.
Key Data Snapshot
What happened
- Biocon Limited approved its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
- The company reported a standalone profit after tax of Rs. 917 million for Q2 2026.
- Dr. Mandar Shrikant Ghatnekar resigned as Chief Technology Officer effective December 31, 2026.
- Mr. Mukesh Rathi was appointed as Chief Technology Officer starting January 1, 2027.
Key details
- Quarterly standalone revenue from operations stood at Rs. 6,305 million for Q2 2026 and Rs. 12,550 million for the half-year.
- Total expenses for the quarter were Rs. 6,014 million.
- Earnings per share for the quarter were Rs. 0.56 (basic and diluted).
- Mr. Mukesh Rathi has over 27 years’ experience in digital transformation and technology leadership roles across major companies including Hinduja Group and Dr. Reddy’s Laboratories.
Regulatory and governance context
- The financial results have been prepared in accordance with Indian Accounting Standards (Ind-AS).
- Disclosure complies with SEBI Listing Regulations, 2015 and recent SEBI circulars dated January 30, 2026.
- The board meeting was held on November 4, 2026, and all disclosures are uploaded on Biocon’s website.
Highlights
- Standalone revenue from operations for Q2 2026: Rs. 6,305 million
- Standalone profit after tax for Q2 2026: Rs. 917 million
- Earnings per share (basic and diluted) for Q2 2026: Rs. 0.56
- CTO Dr. Mandar Ghatnekar to resign effective December 31, 2026
- Mukesh Rathi appointed as new CTO effective January 1, 2027
- Board meeting held on November 4, 2026, from 11:20 A.M. to 1:10 P.M.
Disclosures
- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
Aegis Logistics Ltd. Confirms No Undisclosed Price Sensitive Information Amid Rising Equity Trading Volume
In response to a BSE inquiry on November 4, 2026, Aegis Logistics Ltd. clarified that the recent surge in trading volume of its equity shares is market-driven and based on investor interest tied to the company's performance and prospects. The company confirmed that it is in full compliance with SEBI (LODR) Regulations, 2015, and that no unpublished price sensitive information is pending disclosure.
Read Full Story
